JP2024506940A5 - - Google Patents
Info
- Publication number
- JP2024506940A5 JP2024506940A5 JP2023549820A JP2023549820A JP2024506940A5 JP 2024506940 A5 JP2024506940 A5 JP 2024506940A5 JP 2023549820 A JP2023549820 A JP 2023549820A JP 2023549820 A JP2023549820 A JP 2023549820A JP 2024506940 A5 JP2024506940 A5 JP 2024506940A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amino acid
- acid sequence
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150825P | 2021-02-18 | 2021-02-18 | |
| US63/150,825 | 2021-02-18 | ||
| US202163180892P | 2021-04-28 | 2021-04-28 | |
| US63/180,892 | 2021-04-28 | ||
| US202163226037P | 2021-07-27 | 2021-07-27 | |
| US63/226,037 | 2021-07-27 | ||
| US202163285781P | 2021-12-03 | 2021-12-03 | |
| US63/285,781 | 2021-12-03 | ||
| PCT/US2022/016841 WO2022178159A1 (en) | 2021-02-18 | 2022-02-17 | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506940A JP2024506940A (ja) | 2024-02-15 |
| JP2024506940A5 true JP2024506940A5 (https=) | 2025-02-25 |
Family
ID=82931032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549820A Pending JP2024506940A (ja) | 2021-02-18 | 2022-02-17 | Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体を含む組成物及びその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240309104A1 (https=) |
| EP (1) | EP4294444A4 (https=) |
| JP (1) | JP2024506940A (https=) |
| KR (1) | KR20230157973A (https=) |
| AU (1) | AU2022223420A1 (https=) |
| BR (1) | BR112023016672A2 (https=) |
| CA (1) | CA3207817A1 (https=) |
| CL (1) | CL2023002424A1 (https=) |
| CO (1) | CO2023011969A2 (https=) |
| CR (1) | CR20230436A (https=) |
| DO (1) | DOP2023000162A (https=) |
| EC (1) | ECSP23070237A (https=) |
| GE (2) | GEAP202416596A (https=) |
| IL (1) | IL305312A (https=) |
| JO (1) | JOP20230185A1 (https=) |
| MX (1) | MX2023009622A (https=) |
| PE (1) | PE20231681A1 (https=) |
| TW (1) | TW202246322A (https=) |
| WO (1) | WO2022178159A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230109779A (ko) | 2013-03-27 | 2023-07-20 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전 |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| AU2020275413A1 (en) | 2019-05-14 | 2021-12-23 | Cedars-Sinai Medical Center | TL1A patient selection methods, systems, and devices |
| NZ787680A (en) | 2019-10-24 | 2026-02-27 | Cedars Sinai Medical Center | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| WO2024137353A1 (en) * | 2022-12-22 | 2024-06-27 | Prometheus Biosciences, Inc. | Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors |
| WO2024173838A2 (en) * | 2023-02-17 | 2024-08-22 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the bile duct |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| US20250109209A1 (en) | 2023-10-03 | 2025-04-03 | Absci Corporation | Tl1a associated antibody compositions and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9683998B2 (en) * | 2013-11-13 | 2017-06-20 | Pfizer Inc. | Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof |
| MX392069B (es) * | 2016-05-09 | 2025-03-21 | Bristol Myers Squibb Co | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. |
| KR20190082815A (ko) * | 2016-10-26 | 2019-07-10 | 세다르스-신나이 메디칼 센터 | 중화 항-tl1a 단일 클론 항체 |
| CN112585165B8 (zh) * | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| TW202600603A (zh) * | 2019-10-24 | 2026-01-01 | 美商普羅米修斯生物科學股份有限公司 | 針對類-tnf配體1a (tl1a)之人類化抗體及其用途 |
-
2022
- 2022-02-17 TW TW111105898A patent/TW202246322A/zh unknown
- 2022-02-17 BR BR112023016672A patent/BR112023016672A2/pt unknown
- 2022-02-17 GE GEAP202416596A patent/GEAP202416596A/en unknown
- 2022-02-17 CA CA3207817A patent/CA3207817A1/en active Pending
- 2022-02-17 AU AU2022223420A patent/AU2022223420A1/en active Pending
- 2022-02-17 JP JP2023549820A patent/JP2024506940A/ja active Pending
- 2022-02-17 IL IL305312A patent/IL305312A/en unknown
- 2022-02-17 WO PCT/US2022/016841 patent/WO2022178159A1/en not_active Ceased
- 2022-02-17 KR KR1020237031689A patent/KR20230157973A/ko active Pending
- 2022-02-17 EP EP22756949.8A patent/EP4294444A4/en active Pending
- 2022-02-17 GE GEAP202316354A patent/GEAP202316354A/en unknown
- 2022-02-17 MX MX2023009622A patent/MX2023009622A/es unknown
- 2022-02-17 PE PE2023002389A patent/PE20231681A1/es unknown
- 2022-02-17 CR CR20230436A patent/CR20230436A/es unknown
- 2022-02-17 US US18/546,938 patent/US20240309104A1/en active Pending
-
2023
- 2023-08-09 JO JOJO/P/2023/0185A patent/JOP20230185A1/ar unknown
- 2023-08-16 CL CL2023002424A patent/CL2023002424A1/es unknown
- 2023-08-17 DO DO2023000162A patent/DOP2023000162A/es unknown
- 2023-09-08 CO CONC2023/0011969A patent/CO2023011969A2/es unknown
- 2023-09-14 EC ECSENADI202370237A patent/ECSP23070237A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024506940A5 (https=) | ||
| JP2024508762A5 (https=) | ||
| JP2024016177A5 (https=) | ||
| KR102614259B1 (ko) | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 | |
| JP2020518599A5 (https=) | ||
| JP2016534052A5 (https=) | ||
| JP2020518600A5 (https=) | ||
| RU2011108025A (ru) | Стабильный жидкий препарат антитела | |
| JP2020509031A5 (https=) | ||
| JP2021524231A5 (https=) | ||
| TW200932262A (en) | Remedy for graft-versus-host disease comprising interleukin-6 receptor inhibitor as the active ingredient | |
| JP2024544523A5 (https=) | ||
| JP2025032102A5 (https=) | ||
| JP2024540377A5 (https=) | ||
| JP2024531151A5 (https=) | ||
| JP2023540025A5 (https=) | ||
| US20190010224A1 (en) | Formulations of engineered anti-il-10 antibodies | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| AR124067A2 (es) | Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met | |
| US20250019421A1 (en) | Pharmaceutical formulation comprising bispecific antibody against rabies virus g protein and preparation method therefor | |
| JP2023504748A5 (https=) | ||
| CL2024000232A1 (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| JP2025165988A (ja) | プラスミノーゲンとの結合のための抗体 | |
| JP2022519796A5 (https=) | ||
| CA3064470A1 (en) | Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof |